Ethylisopropyltryptamine
Clinical data | |
---|---|
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
|
|
ChemSpider | 21106305 |
Chemical and physical data | |
Formula | C15H22N2 |
Molar mass | 230.36 g/mol |
3D model (Jmol) | Interactive image |
Melting point | 71 to 73 °C (160 to 163 °F) |
|
|
|
|
(verify) |
EiPT is a chemical in the tryptamine family, and produces psychedelic and hallucinogenic effects. It was probably first synthesized by Alexander Shulgin.
Chemistry[edit]
EiPT is short for N-ethyl-N-isopropyl-tryptamine. The full chemical name of this structure is N-ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-2-amine. EiPT is a tryptamine, which all belong to a larger family of compounds known as indolethylamines. EiPT is closely related to the compounds diethyltryptamine (DET) and DIPT.
Dosage[edit]
In his book TiHKAL, Alexander Shulgin lists a dosage for EiPT as being 24-40 mg taken orally.
Effects[edit]
Very little is known about the psychopharmacological properties of EiPT, but reports suggest it produces psychedelic effects that can last 4-6 hours. According to Shulgin, this compound tends to produce nausea, dysphoria, and other unpleasant side-effects. It also lacks the hallucinatory and visual properties usually associated with psychedelic drugs.
Dangers[edit]
There have been no reported deaths or hospitalizations from EiPT, but its safety profile is unknown.
Legality[edit]
EiPT is unscheduled and uncontrolled in the United States, but possession and sales of EiPT could be prosecuted under the Federal Analog Act because of its structural similarities to DET.